Concord Drugs sets Sep 23 record date for 31st AGM

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • Concord Drugs sets September 23, 2026, as the record date for its 31st AGM
  • The annual general meeting is scheduled for September 30, 2026, via VC/OAVM
  • Book closure period runs from September 24 to September 30, 2026
  • Eligible shareholders can cast electronic votes during the meeting
powered bylight_fuzz_icon
50341581

*this image is generated using AI for illustrative purposes only.

Concord Drugs has fixed Wednesday, September 23, 2026, as the cut-off date for determining shareholders eligible to vote at its 31st Annual General Meeting. The meeting is scheduled for September 30, 2026.

The company notified BSE Limited on September 7, 2026, pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice included the submission of the Annual Report for FY26.

Meeting Details

The AGM will be held on Wednesday, September 30, 2026, starting at 9:30 am. It will be conducted through Video Conferencing or Other Audio Visual Means (VC/OAVM), in compliance with circulars from the Ministry of Corporate Affairs and SEBI.

Shareholder Eligibility and Book Closure

The Register of Members, Share Transfer Books, and other company books will remain closed from September 24, 2026, to September 30, 2026, inclusive. This closure is mandated under Section 91 of the Companies Act, 2013, and Regulation 42 of the SEBI (LODR) Regulations, 2015.

Shareholders on record as of September 23, 2026, will be eligible to cast electronic votes. The Annual Report is available on the company’s website.

Historical Stock Returns for Concord Drugs

1 Day5 Days1 Month6 Months1 Year5 Years
-1.39%-1.76%+11.89%+10.68%+24.53%0.0%

What key financial metrics or strategic initiatives from FY26 are likely to be highlighted in the Annual Report submitted to BSE?

How might the resolution of any special business items at the AGM impact Concord Drugs' future dividend policy or capital allocation strategy?

Are there any anticipated changes to the board composition or management structure that shareholders should prepare for during the vote?

Concord Drugs provides web link to access FY26 annual report

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights
  • Concord Drugs provides web link to FY26 annual report for shareholders with unregistered emails
  • Disclosure made under Regulation 36(1)(b) of SEBI LODR Regulations, 2015
  • 31st AGM scheduled for September 30, 2026, via video conferencing
  • Company urges investors to update email IDs with depository participants
powered bylight_fuzz_icon
50342890

*this image is generated using AI for illustrative purposes only.

Concord Drugs Limited has issued a formal disclosure to the Bombay Stock Exchange regarding the distribution of its Annual Report for the financial year ended March 31, 2026. The company is sending letters to members who have not registered their email addresses with the registrar or depository participants.

Regulatory Compliance and Access

Pursuant to Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Concord Drugs is required to provide a web link and exact path to access the complete annual report for shareholders without registered email IDs. The document is available on the company’s website under the Investor Relations section.

The management urges shareholders to update their email addresses with their respective Depository Participants. This step is essential for receiving future communications electronically in accordance with the Companies Act, 2013, and SEBI LODR regulations.

Upcoming Shareholder Meeting

The company has scheduled its 31st Annual General Meeting for Wednesday, September 30, 2026. The meeting will be held at 9:30 am through Video Conferencing or Other Audio Visual Means, as permitted by the Ministry of Corporate Affairs and SEBI circulars.

Shareholders whose email addresses are registered will receive the AGM notice and the annual report electronically. Those with unregistered emails are directed to use the provided web link to review the documents prior to the meeting.

Historical Stock Returns for Concord Drugs

1 Day5 Days1 Month6 Months1 Year5 Years
-1.39%-1.76%+11.89%+10.68%+24.53%0.0%

How might the shift to fully electronic communication impact Concord Drugs' operational costs and shareholder engagement metrics in FY2027?

What specific financial performance indicators or strategic initiatives are likely to be highlighted in the Annual Report for FY2026 given the current pharmaceutical market trends?

Could the adoption of virtual AGMs lead to increased retail investor participation and voting turnout compared to previous years?

More News on Concord Drugs

1 Year Returns:+24.53%